ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Timolol

Also written as “Timolol Maleate Gel”, “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)” and “timolol 0.5%”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Hemangioma, Capillary, led by 9 companies.

Drug pageTimolol: every studyMany companies study it; this page follows only the 23 they lead. All 84 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 13, 200823 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie80 open or runningphase 4since Aug 13, 2008Aug 13, 2008none ahead
Merckits history only30 open or runningphase 3since Apr 12, 2005Apr 12, 2005none ahead
Santen Pharmaceuticalits history only30 open or runningphase 3since Feb 28, 2011Apr 7, 2009none ahead
Viatrisits history only30 open or runningphase 3since Sep 8, 2005Sep 8, 2005none ahead
Auson Pharmaceuticalsits history only20 open or runningphase 3since Oct 29, 2024Oct 29, 2024none ahead
Credit Valley EyeCareits history only10 open or runningphase 4since Feb 13, 2012Feb 13, 2012none ahead
Glaukosits history only10 open or runningphase 4since Jun 1, 2009Jun 1, 2009none ahead
Laboratorios Poenits history only10 open or runningphase 4since Mar 30, 2023Mar 30, 2023none ahead
Vistakon Pharmaceuticalsits history only10 open or runningphase 4since Dec 5, 2008Dec 5, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 13, 2008First study: phase 4 study in GlaucomaFirst studyNCT00735449 · 204 enrolled · United States, Canada
  2. Feb 12, 2010No phase study in Glaucoma, Open-AngleNCT01068964 · 235 enrolled · China
  3. Oct 5, 2010Phase 1 study in Glaucoma, Open-AngleNCT01215786 · 50 enrolled · United States
  4. Oct 7, 2010Phase 3 study in Glaucoma, Open-AngleNCT01217606 · 185 enrolled · Brazil
  5. Oct 26, 2010No phase study in GlaucomaNCT01229462 · 238 enrolled · China
  6. Nov 12, 2010Phase 3 study in Glaucoma, Open-AngleNCT01241240 · 192 enrolled · Colombia, Mexico
  7. Jun 17, 2013Phase 4 study in GlaucomaNCT01881126 · 93 enrolled · Canada
  8. Mar 25, 2014Phase 4 study in GlaucomaNCT02097719 · 100 enrolled · United States

TargetBeta

ADRB1 →ADRB2 →read by rule
“Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Epinephrinerulenasus-pharmaphase 417

Studies

All 8 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02097719Glaucoma · United States4CompletedDec 2014100
NCT01881126Glaucoma · Canada4CompletedOct 201493
NCT01241240Glaucoma, Open-Angle · Colombia, Mexico3CompletedSep 2013192
NCT01229462Glaucoma · China–CompletedSep 2011238
NCT01217606Glaucoma, Open-Angle · Brazil3CompletedSep 2014185
NCT01215786Glaucoma, Open-Angle · United States1CompletedDec 201050
NCT01068964Glaucoma, Open-Angle · China–CompletedSep 1, 2010235
NCT00735449Glaucoma · United States, Canada4CompletedDec 2009204

How it is read

Names in the registry

  • “Timolol Maleate Gel”, 4 entries
  • “Timolol”, 3 entries
  • “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)”, 2 entries
  • “timolol 0.5%”, 2 entries
  • “timolol maleate”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.